The voluntary action affects devices manufactured before May 12, 2025, after reports of component detachment linked to patient injuries and one death, with Olympus reinforcing safeguards to prioritise patient safety....
The 17,000-woman study, led by Peking University Shenzhen Hospital, sets three world records and integrates PHASiFY™ DNA concentration technology with AI-powered diagnostics to advance scalable, non-invasive screening in line with WHO’s 2030 elimination goals....
The expanded clearance extends BioTraceIO360 beyond liver applications to kidney procedures, advancing Techsomed’s vision of a multi-organ, AI-driven image-guided therapy platform that standardises minimally invasive cancer care....
The study applies PHASE Scientific’s proprietary PHASiFY urine-based DNA concentration technology...
The addition of Blue Spark Technologies, Inc. and QT Medical as device partners signals exciting growth for HeartcoR Solutions as a leading core lab for remote patient monitoring (RPM)...
The COHERENT-AF trial will enrol up to 360 patients across clinical sites in the United States and Europe...
Yang Huang, Head of China Healthcare Research at J.P. Morgan, unpacks how favourable policies, demographic shifts, and global collaborations are shaping the future of biopharma and medtech investment in China. ...
This strategic collaboration aims to advance medical education and clinical training in laparoscopic and minimally invasive surgical techniques...
The outpatient procedures were performed as part of an ongoing FDA IDE clinical trial ...
Medtech firm unveils Axana®, a 50kg, AI-enhanced, portable MRI device that cuts stroke diagnosis time by over 90%—unlocking lifesaving treatment in the golden hour and opening an $8.9bn global market opportunity....
